PAR'S GENERIC PARNATE RECEIVES FDA APPROVAL
The FDA has approved Par Pharmaceutical's generic equivalent of GlaxoSmithKline's depression drug Parnate, the drugmaker said. Par will market the drug in 10-mg tablets.
Annual sales of Parnate (tranylcypromine sulfate) exceed $6 million, Par said.
Parnate was one of 11 antidepressants given a black box warning in January 2005 after the FDA approved labeling revisions to antidepressants to describe the increased risk of suicidal behavior in children and adolescents who take the drugs.